论文部分内容阅读
目的对于晚期转移性乳腺癌患者采取培美曲塞联合奥沙利铂治疗进行临床观察与分析疗效价值。方法选取自2012年10月-2014年10月在入住并接受治疗的108例女性晚期转移性乳腺癌患者作为研究对象,以随机数字表法将其分为试验组和对照组各54例。对照组使用奥沙利铂治疗,试验组则采取培美曲塞联合奥沙利铂治疗。结果 2组患者经治疗后,试验组患者第1年与第2年随访的生存率以及消化道反应发生率、血液学毒性发生率明显高于对照组,差异有统计学意义(P<0.05);试验组患者的神经毒性、肝功能毒性、肾功能毒性与对照组患者的相比,差异无统计学意义(P>0.05)。结论采取培美曲塞联合奥沙利铂治疗疗效肯定,已经成为治疗晚期转移性乳腺癌患者的主要治疗手段,具有较高临床价值。
Objective To evaluate the clinical value and clinical efficacy of pemetrexed combined with oxaliplatin in patients with advanced metastatic breast cancer. Methods One hundred and eighty women with advanced metastatic breast cancer admitted to our hospital from October 2012 to October 2014 were enrolled in this study. They were divided into two groups (n = 54 in each group) by random number table. The control group was treated with oxaliplatin, and the test group was treated with pemetrexed plus oxaliplatin. Results The survival rate, the incidence of digestive tract reaction and the hematological toxicity in the two groups after treatment were significantly higher than those in the control group (P <0.05) There was no significant difference in the neurotoxicity, hepatic toxicity and renal toxicity among the patients in the control group (P> 0.05). Conclusion Pemetrexed combined with oxaliplatin treatment has certain effect, which has become the main treatment for patients with advanced metastatic breast cancer and has high clinical value.